KTTA Stock Catalyst: Pasithea Therapeutics Announced Updated Interim Safety and Clinical Activity Data for PAS-004

Jun 30, 2026 · 7:01am ET

The data is from the trial evaluating PAS-004 in patients with MAPK pathway-driven advanced solid tumors.

Max move

+36.4%

High of day $0.01

Sparker timei

7:01am ET

KTTA · Jun 30, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced updated interim safety and clinical activity data from its trial evaluating PAS-004 in patients with MAPK pathway-driven advanced solid tumors. The announcement was made to provide stakeholders with the latest developments in the trial.

The updated data includes safety assessments and clinical activity observations from the ongoing trial. No specific amounts, filings, or comparators were provided in the announcement.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time KTTA sparks.

Download Sniper App →

Catch the next KTTA-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →